PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986

The medicine is dispensed with a doctor's prescription only

Omnitrope 5 mg/1.5 ml
Omnitrope 10 mg/1.5 ml
Omnitrope 15 mg/1.5 ml

Solution for subcutaneous injection

The active ingredient: SOMATROPIN
For use with the SurePal™ pen injector

Omnitrope 5 mg/1.5 ml:
A cartridge which contains 5 mg somatropin (15 international units) in 1.5 ml solution for injection.

Omnitrope 10 mg/1.5 ml:
A cartridge which contains 10 mg somatropin (30 international units) in 1.5 ml solution for injection.

Omnitrope 15 mg/1.5 ml:
A cartridge which contains 15 mg somatropin (45 international units) in 1.5 ml solution for injection.

Inactive ingredients - see section "Further Information" in the leaflet.

Read this leaflet carefully in its entirety before using the medicine:
This leaflet contains concise information about the medicine; if you have further questions, refer to the doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to others.
It may harm them even if it seems to you that their medical condition is similar.

What should you know before using Omnitrope?
Before using this medicine, you should be trained by a certified medical team regarding how to prepare and inject the medicine.
For information about side effects, please refer to section 4.

1. WHAT IS THE MEDICINE INTENDED FOR?

In children:
Treatment of growth problems in children caused by inadequate or complete lack of secretion of growth hormone from the pituitary gland (hypophysis).
- Growth problems due to Turner syndrome
- Growth delay in children due to kidney failure
- Children born small for gestational age (SGA)
- Prader-Willi Syndrome

In adults:
1. For adults suffering from growth hormone deficiency from childhood.
2. For adults suffering from growth hormone deficiency due to a problem with the pituitary gland.

Therapeutic group: Growth hormone
Omnitrope is a recombinant growth hormone (also called SOMATROPIN)

2. BEFORE USING THE MEDICINE

☒ Do not use the preparation if:
x you have a known sensitivity to somatropin or to any of the inactive ingredients of the medicine.
x Do not use the medicine in patients with evidence of tumors.
If a tumor was diagnosed, finish treating it before starting treatment with Omnitrope.
Do not use the medicine in patients with an active intracranial tumor.
x Do not use the medicine to stimulate growth in children with closed epiphyses.
x Do not use in patients suffering from acute complications following open-heart surgery, abdominal surgeries, multisystem trauma, respiratory failure and similar situations.
x In patients with chronic kidney disease treatment with Omnitrope should be discontinued before a kidney transplant.
x Do not use Omnitrope if you had a kidney transplant.
x Do not use the medicine in patients with Prader-Willi syndrome suffering from severe obesity and severe respiratory disturbances.
x Do not use Omnitrope if you are suffering from diabetic retinopathy (disease of the retina).

Do not use the medicine without consulting a doctor before starting treatment:
! Consult the doctor before starting treatment if you are pregnant or breastfeeding. Inform the doctor immediately if you discover that you are pregnant, suspect you are pregnant or if you are planning to become pregnant or to breastfeed.
! If you are suffering, or have suffered in the past, from impaired function of: the kidney, thyroid.
! If you are suffering, or have suffered in the past, from diabetes.

Special warnings regarding use of this medicine:
! If you are sensitive to any food or medicine, inform the doctor before taking the medicine.
! Inform the doctor if you are sick with a serious illness (e.g., heart and abdominal surgeries, respiratory failure, multisystem trauma, etc.) during the course of treatment.
! Before starting treatment with the medicine, other medical causes of growth disturbances should be ruled out in children born short.
! SGA patients (children born short for their gestational age) should be tested for fasting blood glucose and insulin levels before starting treatment with the preparation, as well as every year thereafter, in addition, insulin like growth factor-1 (IGF-1) should be tested before start of treatment and twice a year thereafter.
! Patients with Prader-Willi syndrome should be evaluated for presence of an upper respiratory airway obstruction and sleep apnea before starting treatment with Omnitrope; in these patients, the treatment should be combined with a suitable diet (see section 2 "Do not use this preparation if"). Signs of respiratory tract infection, such as onset or worsening of snoring and scoliosis in children should also be monitored in these patients.
! There is limited information regarding treatment of patients above the age of 80 and long-term treatment of adults and Prader-Willi syndrome patients.
! A glucose tolerance test should be performed in patients with risk of diabetes (e.g., family history of diabetes, obesity, insulin resistance, abnormal skin pigmentation).
! Patients suffering from diabetes should have blood sugar levels monitored during the course of treatment with Omnitrope and assess with the attending doctor the need for a change in the dosage of the diabetes medicines.
! If you have been diagnosed in the past with a tumor, you should undergo frequent tests for detection of tumor recurrence.
! Thyroid function should be periodically monitored during the course of treatment. In some patients, there may be a need to begin treatment with thyroid hormones. Patients being treated with thyroid hormones may need to have their dosage adjusted at the start of treatment with Omnitrope.
! Inform the doctor of onset of limping or any other complaint of pain in the hip or knee.
! Inform the attending doctor in the event of a severe headache, vomiting or vision disturbance, signs of increased intracranial pressure.
! Inform the doctor in the event of worsening of a stomachache.
! Kidney function and growth should be monitored before starting treatment with Omnitrope. In addition, growth rate should be monitored upon administration of Omnitrope.
! Omnitrope 5 mg/1.5 ml contains benzyl alcohol (section 6 "Further Information") therefore must not be given to premature babies and neonates.
Benzyl alcohol may cause toxic reactions and allergic reactions in children under 3 years of age.

! If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist.
• In particular, inform the doctor if you are taking medicines from the following groups: sex hormones, corticosteroids, epilepsy medicines, cyclosporin, medicines to treat diabetes and medicines to treat thyroid dysfunction, since in combination of Omnitrope, the blood levels of these medicines decline.

! Pregnancy and breastfeeding
It is very important to consult a doctor if you are pregnant, planning a pregnancy or are breastfeeding.

! Important information regarding some of the ingredients of the medicine:
The preparation contains negligible amounts of salt (sodium) and is defined as "salt-free".
Omnitrope 5 mg/1.5 ml contains benzyl alcohol (pay attention to the section "Special warnings regarding use of this medicine").

3. HOW SHOULD YOU USE THE MEDICINE?

Always use according the doctor's instructions. Do not exceed the recommended dose; check with the doctor or pharmacist if you are uncertain.
The dosage and the treatment regimen will be determined by the attending doctor only, after injecting the medicine for the first time in the clinic and under the supervision by one of the team members, and adjustment of the dosage for each individual patient. The medicine is intended for subcutaneous injection.

You should undergo training regarding preparation and injection of the medicine by a certified medical team.

Do not exceed the recommended dose.

Injection instructions:
Omnitrope is administered via the SurePal™ pen injector, which enables multiple use.
- Omnitrope is provided in a cartridge which contains the preparation in concentrations of 5 mg, 10 mg, 15 mg.
- The cartridge intended for injection is inserted into the dedicated SurePal™ pen injector.

Detailed instructions about how to inject and how to use the SurePal™ pen injector are provided with the package, in four languages.

A separate leaflet will be given to the patient or caregiver by the medical team, and will contain a detailed explanation of the SurePal™ pen injector (pen injector dedicated for Omnitrope).

! If you accidentally took a higher dosage or if a child has accidentally injected a large quantity, immediately refer to a doctor or proceed to a hospital emergency room and bring the package of the medicine with you.
! If you forgot to inject this medicine, or if you injected too little, refer to the attending doctor. Never inject two doses together!
! Adhere to the treatment regimen recommended by the doctor. Even if there is an improvement in your health, do not stop the treatment with the medicine without consulting the doctor.
! Do not take medicines in the dark! Check the label and the dose each time you take medicine. Wear glasses if you need them.
If you have further questions regarding the use of the medicine, consult the doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, use of Omnitrope may cause side effects in some users. Do not be alarmed by the list of side effects. You may not suffer from any of them.

Discontinue treatment with Omnitrope and refer to a doctor immediately if:
You are suffering from muscle aches and/or unusual pain at the injection site, limping in one leg, severe or recurrent headaches, vision disturbances, nausea and/or vomiting, symptoms of blockage of the upper respiratory airways (onset or worsening of snoring), if you became ill with a severe disease.

Continue treatment and refer to a doctor as soon as possible if:
You are suffering from increased thirst, increased urination, fatigue (signs which may be indicative of type 2 diabetes), severe stomach pain.

Very common side effects (occur in more than one in ten users):
In adults: joint pain, edema of the hands or legs

Common side effects (occur in 1-10 in 100 users):
In children: temporary redness, stinging or pain at the injection site, joint pain
In adults: stiffness of the arms and legs, muscle pain, numbness or stinging sensation of pain or burning in the hands or armpit (Carpal tunnel syndrome).
These effects usually occur at the beginning of treatment and usually pass after the adaptation period to the medicine or upon reduction of the dose; however, if the aforementioned effects persist and/or are bothersome, refer to a doctor.

Uncommon side effects (occur in 1-10 in 1000 users):
In children: edema of the hands and legs, which occurs for a short time at the start of treatment

Rare side effects (occur in 1-10 in 10000 users):
In children: numbness or stinging, leukemia, increased intracranial pressure (manifested by symptoms such as severe headaches, vision disturbances or vomiting), muscle pain.

Additional side effects of unknown frequency:
Type 2 diabetes, reduced blood cortisol levels.
In children: stiffness of the arms and legs
In adults: increased intracranial pressure (manifested by symptoms such as severe headaches, vision disturbances or vomiting), redness, stinging or pain at the injection site.

Additional side effects:
Development of antibodies against the medicine, rough or lumpy skin at the injection site (can be prevented by injecting into a different place at each injection).
There have been very rare cases of sudden death in Prader-Willi syndrome patients, however no link to treatment with this medicine has been proven.
Discomfort or pain in the hip or knee joint.
High blood glucose levels, low thyroid hormone levels – the doctor will refer you for tests; if necessary, he will give you appropriate treatment.

If one of the side effects worsens, or if you suffer from a side effect not mentioned in the leaflet, consult with the doctor.

Side effects can be reported to the Ministry of Health by clicking on the link "Report Side Effects of Drug Treatment" found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link: https://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il

5. HOW SHOULD THE MEDICINE BE STORED?

- Avoid poisoning! This medicine, and any other medicine, should be kept in a safe place out of the reach of children and/or infants in order to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month.
- Store in the refrigerator, at a temperature of 2-8°C; do not freeze the product.
- Store the cartridge in its original package to protect from light.
- After first use, the cartridge should be left in the SurePal™ pen injector and at a temperature of 2-8°C for a period that does not exceed 28 days from the day it was opened.
- Do not use the preparation:
  ◦ If the solution is cloudy or contains particles
  ◦ If the solution was accidentally frozen.

6. FURTHER INFORMATION

Inactive ingredients:
Omnitrope 5 mg:
Disodium hydrogen phosphate heptahydrate, Sodium dihydrogen phosphate dihydrate, Poloxamer 188, Benzyl alcohol, Mannitol, Phosphoric acid, Sodium hydroxide, Water for injections
Omnitrope 10 mg:
Disodium hydrogen phosphate heptahydrate, Sodium dihydrogen phosphate dihydrate, Poloxamer 188, Phenol, Glycin, Phosphoric acid, Sodium hydroxide, Water for injections
Omnitrope 15 mg:
Disodium hydrogen phosphate heptahydrate, Sodium dihydrogen phosphate dihydrate, Sodium chloride, Poloxamer 188, Phenol, Phosphoric acid, Sodium hydroxide, Water for injections

What the medicine looks like and the contents of the package:
Omnitrope is a clear, colorless solution provided in a cartridge intended for injection with the dedicated SurePal™ pen injector.

Registration holder and address: Novartis Israel Ltd., 36 Shacham St., Petach-Tikva.

Manufacturer and address: Sandoz GmbH, Kundl Austria.

The format of this leaflet was determined by the Ministry of Health and its contents were checked and approved in June 2017

Registration number in the National Drug Registry of the Ministry of Health:
OMNITROPE 5 MG/1.5 ML
157 95 34435 00
OMNITROPE 10 MG/1.5 ML
157 96 34436 00
OMNITROPE 15 MG/1.5 ML
157 97 34437 00

OMNITROPE 5 MG, 10 MG, 15 MG PEN INJECTOR

Instructions for use for the patient:
- Below are instructions how to use the preparation.
- Read the instructions carefully and follow the steps in the order in which they appear below.
- Before using the medicine, you should be trained by a certified medical team regarding how to use the preparation.
- Do not attempt to inject Omnitrope if you have not mastered the steps required for successful injection.

1. PREPARATION:
Prepare the following items before the injection:



✓ An Omnitrope 5 mg, 10 mg, 15 mg cartridge, as per the doctor's recommendation.
✓ A SurePal™ pen – a pen injector specially developed for the administration of Omnitrope; this pen injector is not supplied with the preparation, rather, is provided by the medical team.
✓ A single-use needle for subcutaneous injection.
✓ 2 alcohol swabs (be sure to get from the medical team).

Wash your hands thoroughly before use

2. ADMINISTERING OMNITROPE:



- Using an alcohol swab, disinfect the rubber membrane of the Omnitrope cartridge
- Check that the solution is clear and colorless
- Insert the cartridge into the SurePal™ pen injector (insertion instructions are provided with the SurePal™ pen injector)
- Set the dosage recommended by the doctor on the SurePal™ pen injector
- Choose an injection site. It is recommended to choose sites that have a layer of fat between the skin and muscle, e.g., the thigh or belly.
- Inject at a distance of at least 1 cm from the previous site of injection.



- Change the injection site from one injection to another, as you have been trained to do.
- Clean the skin at the injection site with an alcohol swab
- Wait for the spot to dry.
- Insert the needle into the injection site, as explained to you at the training session.

3. AFTER INJECTION:
- After the injection, press the injection site using a sterile, dry pad.
- Do not massage the injection site.
- Cover the needle of the pen injector with the cap, remove the injection needle from the SurePal™ pen injector and discard it. This will keep the Omnitrope solution clear and sterile and will prevent air from entering the pen and blocking it.
- The needle is intended for your use only; after use, do not use it again or give it to someone else.
- Do not share the SurePal™ pen injector with other people.
- Keep the Omnitrope cartridge in the pen injector, with the pen cover, and store in the refrigerator (at a temperature of 2-8°C).
- Confirm that the solution is clear after taking out of the refrigerator. Do not use the product if the solution is cloudy and contains particles.